Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

as an (asymptomatic) adverse event, the gastrointestinal adverse event profile was similar in incidence to that reported for other currently marketed phosphate binders. There was no increase in serum calcium noted in the study.

Dr. Julia Lewis, Professor of Medicine at Vanderbilt University, the Principal Investigator in the study, commented, "This study, as well as earlier studies, suggest that Zerenex is an effective, tolerated phosphate binder that will potentially make a significant clinical addition to treating the important universally present problem of hyperphosphatemia in patients with end-stage renal disease."

Ron Bentsur, Chief Executive Officer of Keryx, stated, "The promising safety and efficacy profile of Zerenex indicates that there is significant market potential for the drug in the phosphate binder space." Mr. Bentsur continued, "We're excited to have two late stage clinical drug candidates, Zerenex and KRX-0401 (perifosine), both with compelling Phase 2 data."

About Hyperphosphatemia

In the United States, according to data from the U.S. Renal Data System, there are approximately 485,000 patients with end-stage renal disease, or ESRD, and the number of ESRD patients is projected to rise 60% to approximately 785,000 by 2020. The majority of ESRD patients, over 350,000, require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism (and its related cardiovascular complications), renal osteodystrophy and soft tissue mineralization. ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of ESRD as well as shortcomings with current therapies. Zerenex has the potential to be an ef
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... its Fiscal Year 2009" issued on 15 Mar,2010 13:20 GMT , by Health Robotics over PR Newswire, we are ... Complete, corrected release follows: , ... , ... ...
... radionuclide - , ... ... - Interaction of ... , ...
... and OXFORD, England , March ... PharmaVentures Limited ("PharmaVentures"),today announced the signing of a ... biotech, pharmaceutical and med tech sectors.,The companies will ... consolidation opportunities which bring together both strategic,expertise and ...
Cached Biology Technology:/C O R R E C T I O N -- Health Robotics/ 2/C O R R E C T I O N -- Health Robotics/ 3/C O R R E C T I O N -- Health Robotics/ 4/C O R R E C T I O N -- Health Robotics/ 5/C O R R E C T I O N -- Health Robotics/ 6/C O R R E C T I O N -- Health Robotics/ 7/C O R R E C T I O N -- Health Robotics/ 8/C O R R E C T I O N -- Health Robotics/ 9/C O R R E C T I O N -- Health Robotics/ 10/C O R R E C T I O N -- Health Robotics/ 11/C O R R E C T I O N -- Health Robotics/ 12/C O R R E C T I O N -- Health Robotics/ 13/C O R R E C T I O N -- Health Robotics/ 14/C O R R E C T I O N -- Health Robotics/ 15/C O R R E C T I O N -- Health Robotics/ 16/C O R R E C T I O N -- Health Robotics/ 17YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 2YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 3YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 4YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 5YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 6YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 7Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 2Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 3Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 4
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
(Date:7/10/2014)... , July 1, 2014 Smart technology ... for convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay ... GOOG ), Apple Inc. (NASDAQ: AAPL ), ... (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... announce that the second series of 30 second spots on ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... A team composed of Harvard students and alumni ... Africa 2008 Development Marketplace competition, held in Accra, Ghana ... fuel cell-based lighting systems suitable for Sub-Saharan Africa, netted ... World Bank, as only 26 percent of Africas population ...
... ARBOR, Mich.---The mouse is a stalwart stand-in for humans ... percent identical. But identical genes may behave differently in ... evolutionary biologists Ben-Yang Liao and Jianzhi Zhang reveals. ... mouse models in studying human disease, appear in the ...
... Japanese researchers have found a strong link between tooth ... head and neck, and lung. They suggest that preservation ... In the May issue of Cancer Epidemiology, Biomarkers ... Cancer Research, scientists from Aichi Cancer Center in Nagoya ...
Cached Biology News:Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 2Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 3Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2